Tiziana Life Sciences – Appointment of Director February 5, 2021 – Posted in: Tiziana Life Sciences (TILS)

5th February, 2021 APPOINTMENT OF DIRECTOR Tiziana Life Sciences plc (NASDAQ: TLSA / LSE: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, today announces the appointment of Dr Thomas Adams, Ph.D. as an executive director. Dr Adams will assume the position of Head of Drug Development with immediate effect and his executive role will be to manage and oversee all matters relating to the Company’s pre-clinical and clinical…

Tiziana Life Sciences – CEO interview February 3, 2021 – Posted in: Tiziana Life Sciences (TILS), Uncategorized

3rd February, 2021 Tiziana Life Sciences CEO Discusses COVID-19 Trial Data in Exclusive Interview Tiziana Life Sciences plc (NASDAQ:TLSA/LSE:TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, today announced an interview with Dr. Kunwar Shailubhai, CEO and CSO, is now available. In the exclusive interview, Dr. Shailubhai discusses the positive effect of nasally administered Foralumab in COVID-19 mediated pulmonary and systemic inflammation and its potential related…

Tiziana Life Sciences – Positive Data from Clinical Study of Nasal Administration with Foralumab February 2, 2021 – Posted in: Tiziana Life Sciences (TILS)

2nd February, 2021 THIS ANNOUNCEMENT INCLUDES INSIDE INFORMATION Tiziana Reports Positive Data from the Clinical Study of Nasal Administration with Foralumab, its proprietary fully human anti-CD3 monoclonal antibody, in COVID-19 Patients in Brazil · Since the anti-inflammatory effect of the nasally administered Foralumab is through the modulation of the immune system and not by directly targeting COVID-19, this therapeutic approach might also be useful for newly identified Covid-19 variants in UK, South Africa and Brazil. · Foralumab is also the first monoclonal…

Tiziana Life Sciences – Initiation of Clinical Trial for COVID-19 Patients in Brazil November 2, 2020 – Posted in: Tiziana Life Sciences (TILS)

2nd November, 2020 Tiziana Life Sciences PLC (“Tiziana” or “the Company”) Tiziana Announces Initiation of Clinical Trial for COVID-19 Patients in Brazil with Nasally Administered Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody London/New York, 2 November 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, announces initiation of a collaborative clinical study investigating nasally administered Foralumab either alone or in…

Tiziana Life Sciences October 26, 2020 – Posted in: Tiziana Life Sciences (TILS)

26th October, 2020 Tiziana Life Sciences Plc (“Tiziana” or the “Company”) Exercise of options, Issue of Equity PDMR Dealing and Total Voting Rights Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces that it has allotted and issued 329,225 ordinary shares of 3 pence each (“New Ordinary Shares”) credited as fully paid at a price of…

Tiziana Life Sciences – Exercise of Warrants & Issue of Equity & Total Voting Rights July 24, 2020 – Posted in: Uncategorized

24th July, 2020 Tiziana Life Sciences plc (“Tiziana” or the “Company”) Exercise of Warrants and Issue of Equity and Total Voting Rights London, New York, 24 July 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces that it has allotted and issued 88,580 ordinary shares of 3 pence each (“New Ordinary Shares”) credited as fully paid in respect of…

Tiziana Life Sciences #TILS – Appoints Optiva Securities Limited as Broker June 1, 2020 – Posted in: Uncategorized

Tiziana Life Sciences plc (AIM:TILS) is pleased to announce the appointment of Optiva Securities Limited as its broker with immediate effect. Enquiries: Gabriele Cerrone, Chairman and founder +44 (0)20 7495 2379 Cairn Financial Advisers LLP (Nominated adviser) Liam Murray / Jo Turner …

Tiziana Life Sciences #TILS presents StemPrintER, a superior prognostic test compared to Oncotype DX to predict breast cancer May 29, 2020 – Posted in: Tiziana Life Sciences (TILS)

Tiziana Life Sciences announces presentation of StemPrintER, a superior prognostic test as compared to Oncotype DX to predict breast cancer · StemPrintER Outperforms Oncotype DX in analysis with 800+ samples from ER+/HER2- postmenopausal breast cancer patients · SPARE Model is up to 40-50% more accurate than standard clinical markers in analysis with 1800+ samples for prediction of distant metastasis New York/London – May 29, 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology…

Tiziana Life Sciences #TILS – Demerger of StemPrintER Genomics-Based Personalized Medicine business as a separate listed company May 22, 2020 – Posted in: Tiziana Life Sciences (TILS)

New York and London, May 22, 2020 – Tiziana Life Sciences plc (NASDAQ: TLSA, AIM: TILS), a clinical stage biotechnology company developing targeted drugs for cancer, inflammatory diseases and COVID-19, today announces that it intends to demerge its StemPrintER and SPARE (together “StemPrintER”) genomics-based personalized medicine businesses into a separate company and effect a capital reduction to facilitate the spin-out and listing of StemPrintER as an independent entity. Following the Company’s recent announcement concerning the…

Tiziana Life Sciences #TILS – Exercise of Warrants and Issue of Equity May 18, 2020 – Posted in: Tiziana Life Sciences (TILS)

London, New York, 18 May 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the “Company” or “Tiziana”), a US and UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology, today announces that it has allotted and issued 264,286 ordinary shares of 3 pence each (“New Ordinary Shares”) credited as fully paid in respect of the exercise of 264,286 warrants at…

1
2
3
4
5
6
Next
Last »